Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer
Background: The incidence of colorectal cancer (CRC) in individuals of fertile age is increasing. Oxaliplatin is a cornerstone treatment in the adjuvant setting for stage III and high-risk stage II CRC. Limited data exist on possible side effects of oxaliplatin on fertility and gonadal function. Mor...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-01-01
|
| Series: | Cancer Treatment and Research Communications |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468294222000090 |
| _version_ | 1828791365771722752 |
|---|---|
| author | Philip Falk Mira Severin Åke Berglund Marianne G. Guren Eva Hofsli Pia Österlund Anne Tandberg Jakob Eberhard Halfdan Sorbye |
| author_facet | Philip Falk Mira Severin Åke Berglund Marianne G. Guren Eva Hofsli Pia Österlund Anne Tandberg Jakob Eberhard Halfdan Sorbye |
| author_sort | Philip Falk |
| collection | DOAJ |
| description | Background: The incidence of colorectal cancer (CRC) in individuals of fertile age is increasing. Oxaliplatin is a cornerstone treatment in the adjuvant setting for stage III and high-risk stage II CRC. Limited data exist on possible side effects of oxaliplatin on fertility and gonadal function. More data is needed to guide possible fertility preservation procedures and aid evidence-based fertility counselling. Patients and methods: The aim of this study (EudraCT2006-002832-10) was to prospectively investigate sex hormones and sperm parameters after oxaliplatin-based adjuvant chemotherapy to clarify the risk of infertility and hypogonadism. Twenty males aged ≤55 years and 16 females aged ≤40 years were recruited from five hospitals in the Nordic countries. All had undergone radical surgery due to CRC and were given adjuvant oxaliplatin in combination with 5-fluorouracil. Measurement of luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone, sex hormone binding globulin (SHBG) and semen analysis were done in males, while LH, FSH and oestradiol were measured in females. Measurements were done prior to chemotherapy, after completion of adjuvant treatment and at follow-up 1 and up to 5 years after end of treatment. Results: FSH and testosterone levels increased in males after chemotherapy treatment but were restored at follow-up. No patients developed hypogonadism. There was a trend towards a decrease in sperm concentration during treatment (p = 0.063). When comparing sperm concentration and rapid progressive motility of sperms prior to chemotherapy and at follow-up, there were no differences, and no patients became permanently azoospermic by treatment. No distinct altering of gonadal function could be observed in females. Conclusions: Oxaliplatin in combination with 5-fluorouracil seems to induce transient decrease in sperm concentration with recovery and a minor transient increase in FSH in males. No distinct altering of gonadal function was observed in females. The risk of infertility and hypogonadism in males and females after adjuvant oxaliplatin-based chemotherapy seems low. |
| first_indexed | 2024-12-12T02:49:38Z |
| format | Article |
| id | doaj.art-3e6fb0374fb14640929b1684072c3445 |
| institution | Directory Open Access Journal |
| issn | 2468-2942 |
| language | English |
| last_indexed | 2024-12-12T02:49:38Z |
| publishDate | 2022-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Cancer Treatment and Research Communications |
| spelling | doaj.art-3e6fb0374fb14640929b1684072c34452022-12-22T00:40:55ZengElsevierCancer Treatment and Research Communications2468-29422022-01-0131100517Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancerPhilip Falk0Mira Severin1Åke Berglund2Marianne G. Guren3Eva Hofsli4Pia Österlund5Anne Tandberg6Jakob Eberhard7Halfdan Sorbye8Department of Oncology, Skåne University Hospital, Lund, Backnejlikegatan 14, Kristianstad 29158, Sweden; Corresponding author.Department of Oncology, Skåne University Hospital, Lund, Backnejlikegatan 14, Kristianstad 29158, SwedenDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, SwedenDepartment of Oncology, Oslo University Hospital, Oslo, NorwayDepartment of Oncology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, NorwayDepartment of Oncology, Tampere University Hospital and Tampere University, Tampere, Finland; Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Department of Oncology, Helsinki University Hospital and Helsinki University, Helsinki, FinlandDepartment of Gynecology, Haukeland University Hospital, Bergen, NorwayDepartment of Oncology, Skåne University Hospital, Lund, Backnejlikegatan 14, Kristianstad 29158, SwedenDepartment of Oncology and Clinical Science, Haukeland University Hospital, Bergen, NorwayBackground: The incidence of colorectal cancer (CRC) in individuals of fertile age is increasing. Oxaliplatin is a cornerstone treatment in the adjuvant setting for stage III and high-risk stage II CRC. Limited data exist on possible side effects of oxaliplatin on fertility and gonadal function. More data is needed to guide possible fertility preservation procedures and aid evidence-based fertility counselling. Patients and methods: The aim of this study (EudraCT2006-002832-10) was to prospectively investigate sex hormones and sperm parameters after oxaliplatin-based adjuvant chemotherapy to clarify the risk of infertility and hypogonadism. Twenty males aged ≤55 years and 16 females aged ≤40 years were recruited from five hospitals in the Nordic countries. All had undergone radical surgery due to CRC and were given adjuvant oxaliplatin in combination with 5-fluorouracil. Measurement of luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone, sex hormone binding globulin (SHBG) and semen analysis were done in males, while LH, FSH and oestradiol were measured in females. Measurements were done prior to chemotherapy, after completion of adjuvant treatment and at follow-up 1 and up to 5 years after end of treatment. Results: FSH and testosterone levels increased in males after chemotherapy treatment but were restored at follow-up. No patients developed hypogonadism. There was a trend towards a decrease in sperm concentration during treatment (p = 0.063). When comparing sperm concentration and rapid progressive motility of sperms prior to chemotherapy and at follow-up, there were no differences, and no patients became permanently azoospermic by treatment. No distinct altering of gonadal function could be observed in females. Conclusions: Oxaliplatin in combination with 5-fluorouracil seems to induce transient decrease in sperm concentration with recovery and a minor transient increase in FSH in males. No distinct altering of gonadal function was observed in females. The risk of infertility and hypogonadism in males and females after adjuvant oxaliplatin-based chemotherapy seems low.http://www.sciencedirect.com/science/article/pii/S2468294222000090Colorectal cancerChemotherapyOxaliplatinFertilitySperm function |
| spellingShingle | Philip Falk Mira Severin Åke Berglund Marianne G. Guren Eva Hofsli Pia Österlund Anne Tandberg Jakob Eberhard Halfdan Sorbye Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer Cancer Treatment and Research Communications Colorectal cancer Chemotherapy Oxaliplatin Fertility Sperm function |
| title | Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer |
| title_full | Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer |
| title_fullStr | Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer |
| title_full_unstemmed | Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer |
| title_short | Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer |
| title_sort | sex hormones and sperm parameters after adjuvant oxaliplatin based treatment for colorectal cancer |
| topic | Colorectal cancer Chemotherapy Oxaliplatin Fertility Sperm function |
| url | http://www.sciencedirect.com/science/article/pii/S2468294222000090 |
| work_keys_str_mv | AT philipfalk sexhormonesandspermparametersafteradjuvantoxaliplatinbasedtreatmentforcolorectalcancer AT miraseverin sexhormonesandspermparametersafteradjuvantoxaliplatinbasedtreatmentforcolorectalcancer AT akeberglund sexhormonesandspermparametersafteradjuvantoxaliplatinbasedtreatmentforcolorectalcancer AT mariannegguren sexhormonesandspermparametersafteradjuvantoxaliplatinbasedtreatmentforcolorectalcancer AT evahofsli sexhormonesandspermparametersafteradjuvantoxaliplatinbasedtreatmentforcolorectalcancer AT piaosterlund sexhormonesandspermparametersafteradjuvantoxaliplatinbasedtreatmentforcolorectalcancer AT annetandberg sexhormonesandspermparametersafteradjuvantoxaliplatinbasedtreatmentforcolorectalcancer AT jakobeberhard sexhormonesandspermparametersafteradjuvantoxaliplatinbasedtreatmentforcolorectalcancer AT halfdansorbye sexhormonesandspermparametersafteradjuvantoxaliplatinbasedtreatmentforcolorectalcancer |